MBX Biosciences, Inc. (MBX)
33.00
+2.01
(+6.49%)
USD |
NASDAQ |
Jun 11, 11:47
MBX Biosciences Shareholders Equity (Quarterly) : 437.76M for March 31, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 437.76M |
| December 31, 2025 | 369.22M |
| September 30, 2025 | 387.54M |
| June 30, 2025 | 219.24M |
| March 31, 2025 | 235.42M |
| Date | Value |
|---|---|
| December 31, 2024 | 257.44M |
| September 30, 2024 | 271.37M |
| June 30, 2024 | 54.47M |
| March 31, 2024 | 69.31M |
| December 31, 2023 | 79.89M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 562.30M |
| Corcept Therapeutics, Inc. | 637.99M |
| Assertio Holdings, Inc. | 75.63M |
| Veru, Inc. | 34.79M |
| Johnson & Johnson | 81.19B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 452.70M |
| Total Liabilities (Quarterly) | 14.94M |
| Debt to Equity Ratio | 0.0013 |
| Current Ratio | 30.79 |
| Net Debt Paydown Yield | -0.00% |